The Biocon Group is the first corporate entity to kickstart this vaccination centre in Bengaluru
The Biocon Group of Companies inaugurated a vaccination centre at the Bengaluru campus of Syngene International as part of the nationwide drive for mass vaccination of individuals above 45 years of age to protect them against COVID-19. The group has started vaccinating all eligible employees in keeping with its commitment to ensuring the health and safety of its workforce. As a responsible corporate citizen, it will also work closely and in partnership with the Government of Karnataka to create awareness and offer this service to all people who are eligible in the Electronic City area of Bengaluru. The Biocon Group is the first corporate entity to kickstart this vaccination centre in Bengaluru.
The centre was inaugurated in the august presence of health officials and dignitaries from the district administration and the Biocon Group: Manjunath J – District Commissioner, Bengaluru; Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon; Dr Mahesh Bhalgat, Chief Operating Officer, Syngene; Dr Srinivas G- District Health Officer, Bengaluru; Dr Syed Sirajjuddin- RCHO & District Immunization Officer, Bengaluru; Dr Manohar -District Surveillance Officer, Bengaluru; Shri Dinesh P – Tehsildar, Anekal Taluk; Dr Vinay Kumar M – Taluk Officer, Anekal; Dr Anil, Sr General Manager, Syngene and Rama NS, CEO, Electronic City Industrial Township Authority (ELCITA).
Manjunath J said, “We have started vaccination drive at workplaces, starting with the Biocon Group situated in the Electronic City. Kiran Mazumdar-Shaw has always been a source of immense support and strength in our COVID containment drive. I express my sincere gratitude to her for enabling us with the vaccination drive at this critical time. Once, all the eligible employees of Biocon Group and their families are vaccinated, this facility will be open to supporting other companies too. I urge everyone above 45+ age group to make the most of this opportunity and get vaccinated.”
Shaw said, “We feel proud and privileged that the Government of Karnataka has given us the first permission as a corporate to initiate vaccination drive for our employees. We will be working closely and in partnership with the government to roll out this vaccination drive, create awareness and offer this service to all people who are eligible in the Electronic City area of Bengaluru, apart from our employees.”
Mahesh Bhalgat, COO, Syngene International said, “The Biocon Group is committed to ensuring the safety and wellbeing of its workforce. Since July 2020, we are proactively testing our employees to identify infection cases and immediately quarantine them and provide necessary medical support. We are now happy to provide free vaccination for our employees and their family. This is an extension of our commitment to safeguarding our employees’ health as well as a reflection of our commitment to support the government’s efforts to combat and contain the pandemic.”
Rama NS said, “This is a professionally managed facility and I recommend all eligible candidates from Electronic City to get vaccinated here. While initially Biocon Group employees will be benefitted from this vaccination drive, the facility will be extended eventually to include other industries and people living around this area. Earlier also, this facility had organized RT-PCR testing for other companies very well.”
Biocon Group of Companies is thankful to the District Administration and the Health Authorities of Bengaluru for granting the license to Syngene Clinical Development Centre, enabling the vaccination drive for COVID-19. Biocon Group of Companies consists of Biocon, Biocon Biologics and Syngene International.
As a part of its commitment to address the novel coronavirus pandemic in India, the Biocon Group is also offering a comprehensive portfolio of products for treating mild to severely ill COVID-19 patients. We have introduced ARAFLU (Favipiravir) in addition to Cytosorb and ALZUMAB-L, and Syngene is manufacturing Remdesivir under a voluntary licensing agreement with Gilead.
